Turnbull P C
Division of Biologics, Public Health Laboratory Service Centre for Applied Microbiology and Research, Salisbury, Wiltshire, UK.
Vaccine. 1991 Aug;9(8):533-9. doi: 10.1016/0264-410x(91)90237-z.
Most livestock vaccines in use throughout the world today for immunization against anthrax are derivatives of the live spore vaccine formulated by Sterne in 1937 and still use descendants of his strain 34F2. Credit belongs to this formulation for effective control in many countries with considerable reduction, sometimes complete elimination, of the disease in animals and, since man generally acquires it from livestock, in man also. However, there are some contraindications of its use and situations in which it cannot be easily administered, and room for development of a successor is discussed. The human vaccines, formulated for at-risk occupations and situations, date from the 1950s (UK vaccine) and 1960s (US vaccine). The rather greater need for improvement of these as compared with the veterinary vaccine stimulated valuable research during the 1980s which has led to a number of promising candidate alternatives for the future.
当今世界上大多数用于预防炭疽的家畜疫苗都是1937年由斯特恩研制的活芽孢疫苗的衍生物,至今仍使用他的34F2菌株的后代。这种配方在许多国家有效地控制了该病,使动物中的发病率大幅降低,有时甚至完全消除,而且由于人类通常从家畜身上感染该病,人类中的发病率也有所降低,这归功于这种配方。然而,它的使用存在一些禁忌症,而且在某些情况下不易给药,因此讨论了开发后续疫苗的空间。针对高危职业和情况研制的人类疫苗可追溯到20世纪50年代(英国疫苗)和60年代(美国疫苗)。与兽用疫苗相比,对这些人类疫苗进行改进的需求更为迫切,这在20世纪80年代激发了有价值的研究,从而产生了一些未来有前景的候选替代疫苗。